KEYNOTE-365 cohort B updated results: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)

被引：0

作者：

Kolinsky, Michael Paul

Gravis, Gwenaelle

Mourey, Loic

Piulats, Josep M.

Sridhar, Srikala S.

Romano, Emanuela

Berry, William R.

Gurney, Howard

Retz, Margitta

Appleman, Leonard Joseph

Boegemann, Martin

De Bono, Johann S.

Joshua, Anthony M.

Emmenegger, Urban

Conter, Henry Jacob

Laguerre, Brigitte

Wu, Helen

Schloss, Charles

Poehlein, Christian Heinrich

Yu, Evan Y.

机构：

[1] Cross Canc Inst, Edmonton, AB, Canada

[2] CLCC Inst Paoli Calmettes, Paris, France

[3] SIOG, Toulouse, France

[4] Catalan Inst Oncol, Barcelona, Spain

[5] UHN Princess Margaret Canc Ctr, Toronto, ON, Canada

[6] Inst Curie, Ctr Canc Immunotherapy, Paris, France

[7] Duke Canc Ctr Cary, Cary, NC USA

[8] Macquarie Univ Hosp, Sydney, NSW, Australia

[9] Tech Univ Munich, Rechts Isar Univ Hosp, Munich, Germany

[10] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA

[11] Univ Hosp Muenster, Munster, Germany

[12] Royal Marsden Hosp, London, England

[13] St Vincents Hosp, Kinghorn Canc Ctr, Sydney, NSW, Australia

[14] Sunnybrook Res Inst, Toronto, ON, Canada

[15] Univ Western Ontario, Brampton, ON, Canada

[16] Ctr Eugene Marquis, Rennes, France

[17] Merck & Co Inc, Kenilworth, NJ USA

[18] Univ Washington, Seattle, WA 98195 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

103

引用

页数：2

共 50 条

[31] Biomarker analysis of men with enzalutamide (enza)resistant metastatic castration-resistant prostate cancer (mCRPC) treated with pembrolizumab (pembro) plus enza in KEYNOTE-199
Graff, J. N.
Tagawa, S.
Hoimes, C.
Gerritsen, W.
Vaishampayan, U. N.
Elliott, T.
Hwang, C.
Ten Tije, A. J.
Omlin, A. G.
McDermott, R. S.
De Wit, R.
Qiu, P.
Poehlein, C.
Kim, J.
Suttner, L.
Cristescu, R.
Marton, M. J.
Schloss, C.
de Bono, J. S.
Antonarakis, E. S.
ANNALS OF ONCOLOGY, 2021, 32 : S383 - S383
[32] KEYNOTE-365 COHORT C: PEMBROLIZUMAB plus ENZALUTAMIDE IN PATIENTS WITH ABIRATERONE ACETATE-PRETREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)-DATA AFTER MINIMUM OF 22 MONTHS OF FOLLOW-UP
Appleman, Leonard
Todenhoefer, Tilman
Berry, William
Gurney, Howard
Retz, Margitta
Conter, Henry
Laguerre, Brigitte
Fong, Peter
Ferrario, Cristiano
Gravis, Gwenaelle
Piulats, Josep
Emmenegger, Urban
Shore, Neal
Romano, Emanuela
Mourey, Loic
Li, Xin Tong
Poehlein, Christian
Schloss, Charles
De Bono, Johann
Yu, Evan
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A374 - A374
[33] Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study
Yu, Evan Y.
Berry, William R.
Gurney, Howard
Retz, Margitta
Conter, Henry J.
Laguerre, Brigitte
Fong, Peter C. C.
Ferrario, Cristiano
Todenhofer, Tilman
Gravis, Gwenaelle
Piulats, Josep M.
Emmenegger, Urban
Shore, Neal D.
Romano, Emanuela
Mourey, Loic
Li, Xin Tong
Poehlein, Christian H.
Schloss, Charles
Appleman, Leonard J.
Bono, Johann S. de
EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (03): : 509 - 518
[34] KEYLYNK-010: Phase III study of pembrolizumab (pembro) plus olaparib (OLA) vs enzalutamide (ENZA) or abiraterone (ABI) in ENZA- or ABI-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who had progression on chemotherapy (CTx)
Yu, E.
Xu, L.
Kim, J.
Antonarakis, E. S.
ANNALS OF ONCOLOGY, 2019, 30
[35] Pembrolizumab (pembro) plus enzalutamide (enza) for enza-resistant metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-199 cohorts 4-5
Graff, Julie Nicole
Antonarakis, Emmanuel S.
Hoimes, Christopher J.
Tagawa, Scott T.
Hwang, Clara
Kilari, Deepak
Ten Tije, A. J.
Omlin, Aurelius Gabriel
McDermott, Raymond S.
Vaishampayan, Ulka N.
Elliott, Anthony
Wu, Helen
Kim, Jeri
Schloss, Charles
De Bono, Johann S.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[36] Effects of abiraterone (ABI) and enzalutamide (ENZA) on cognitive impairment and depressive symptoms in patients (pts) with metastatic castration -resistant prostate cancer (mCRPC).
Parimi, Sunil
Eigl, Bernhard J.
Sunderland, Katherine
Zulficiar, Muhammad
Finch, Daygen L.
Oja, Conrad D.
Vergidis, Joanna
Seto, Leanne Chung-Yon
Azad, Arun
Gleave, Martin
Chi, Kim N.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[37] Phase III study of pembrolizumab (pembro) plus enzalutamide (enza) versus placebo plus enza for metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-641
Graff, Julie Nicole
Burgents, Joseph
Liang, Li Wen
Stenzl, Arnulf
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[38] KEYNOTE-365 cohort D: phase 1b/2 study of pembrolizumab plus abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer
Appleman, Leonard
Piulats, Josep
Mar, Nataliya
Arranz, Jose
Joshua, Anthony
Mayer, Tina
Shore, Neal
Wu, Haiyan
Schloss, Charles
Yu, Evan
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
[39] Phase III study of pembrolizumab (pembro) plus olaparib versus enzalutamide (enza) or abiraterone acetate (abi) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed on chemotherapy: KEYLYNK-010
Yu, Evan Y.
Park, Se Hoon
Huang, Yi-Hsiu
Bennamoun, Mostefa
Xu, Lu
Kim, Jeri
Antonarakis, Emmanuel S.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[40] Cabozantinib (C) plus docetaxel (D) and prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).
Karzai, Fatima
Madan, Ravi Amrit
Theoret, Marc Robert
Arlen, Philip M.
Dawson, Nancy Ann
Rosner, Inger L.
McLeod, David G.
Wright, John Joseph
Cordes, Lisa M.
Couvillon, Anna
Chun, Guinevere
Harold, Nancy
Steinberg, Seth M.
Trepel, Jane B.
Price, Douglas K.
Gulley, James L.
Figg, William Douglas
Dahut, William L.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)

← 1 2 3 4 5 →